These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 25630418)

  • 21. Computational analysis of plasmepsin IV bound to an allophenylnorstatine inhibitor.
    Gutiérrez-de-Terán H; Nervall M; Dunn BM; Clemente JC; Aqvist J
    FEBS Lett; 2006 Oct; 580(25):5910-6. PubMed ID: 17045991
    [TBL] [Abstract][Full Text] [Related]  

  • 22. New paradigm of an old target: an update on structural biology and current progress in drug design towards plasmepsin II.
    Dan N; Bhakat S
    Eur J Med Chem; 2015 May; 95():324-48. PubMed ID: 25827401
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Design and discovery of plasmepsin II inhibitors using an automated workflow on large-scale grids.
    Degliesposti G; Kasam V; Da Costa A; Kang HK; Kim N; Kim DW; Breton V; Kim D; Rastelli G
    ChemMedChem; 2009 Jul; 4(7):1164-73. PubMed ID: 19437467
    [TBL] [Abstract][Full Text] [Related]  

  • 24. On the orientation of the catalytic dyad in aspartic proteases.
    Friedman R; Caflisch A
    Proteins; 2010 May; 78(6):1575-82. PubMed ID: 20112416
    [TBL] [Abstract][Full Text] [Related]  

  • 25. New organofluorine building blocks: inhibition of the malarial aspartic proteases plasmepsin II and IV by alicyclic alpha,alpha-difluoroketone hydrates.
    Fäh C; Hardegger LA; Baitsch L; Schweizer WB; Meyer S; Bur D; Diederich F
    Org Biomol Chem; 2009 Oct; 7(19):3947-57. PubMed ID: 19763297
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Conformational flexibility of beta-secretase: molecular dynamics simulation and essential dynamics analysis.
    Xiong B; Huang XQ; Shen LL; Shen JH; Luo XM; Shen X; Jiang HL; Chen KX
    Acta Pharmacol Sin; 2004 Jun; 25(6):705-13. PubMed ID: 15169620
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Protein surface roughness accounts for binding free energy of Plasmepsin II-ligand complexes.
    Valdés-Tresanco ME; Valdés-Tresanco MS; Valiente PA; Cocho G; Mansilla R; Nieto-Villar JM
    J Mol Recognit; 2018 Jan; 31(1):. PubMed ID: 28895236
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Improvement of both plasmepsin inhibitory activity and antimalarial activity by 2-aminoethylamino substitution.
    Miura T; Hidaka K; Uemura T; Kashimoto K; Hori Y; Kawasaki Y; Ruben AJ; Freire E; Kimura T; Kiso Y
    Bioorg Med Chem Lett; 2010 Aug; 20(16):4836-9. PubMed ID: 20634066
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Discovery of non-peptide inhibitors of Plasmepsin II by structure-based virtual screening.
    Song Y; Jin H; Liu X; Zhu L; Huang J; Li H
    Bioorg Med Chem Lett; 2013 Apr; 23(7):2078-82. PubMed ID: 23466235
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Exploring the pH- and Ligand-Dependent Flap Dynamics of Malarial Plasmepsin II.
    Henderson JA; Shen J
    J Chem Inf Model; 2022 Jan; 62(1):150-158. PubMed ID: 34964641
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Characterisation of hydrazides and hydrazine derivatives as novel aspartic protease inhibitors.
    Ahmed W; Rani M; Khan IA; Iqbal A; Khan KM; Haleem MA; Azim MK
    J Enzyme Inhib Med Chem; 2010 Oct; 25(5):673-8. PubMed ID: 20063996
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Explicit solvent dynamics and energetics of HIV-1 protease flap opening and closing.
    Sadiq SK; De Fabritiis G
    Proteins; 2010 Nov; 78(14):2873-85. PubMed ID: 20715057
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Exploring the flap pocket of the antimalarial target plasmepsin II: the "55 % rule" applied to enzymes.
    Zürcher M; Gottschalk T; Meyer S; Bur D; Diederich F
    ChemMedChem; 2008 Feb; 3(2):237-40. PubMed ID: 17918177
    [No Abstract]   [Full Text] [Related]  

  • 34. Molecular dynamics simulations of the three dimensional model of plasmepsin II-peptidic inhibitor complexes.
    Pranav Kumar SK; Kulkarni VM
    Drug Des Discov; 2001; 17(4):293-313. PubMed ID: 11765133
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dietary flavonoids fisetin and myricetin: dual inhibitors of Plasmodium falciparum falcipain-2 and plasmepsin II.
    Jin H; Xu Z; Cui K; Zhang T; Lu W; Huang J
    Fitoterapia; 2014 Apr; 94():55-61. PubMed ID: 24468190
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A molecular dynamics study comparing a wild-type with a multiple drug resistant HIV protease: differences in flap and aspartate 25 cavity dimensions.
    Seibold SA; Cukier RI
    Proteins; 2007 Nov; 69(3):551-65. PubMed ID: 17623840
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Potent inhibitors of the Plasmodium falciparum enzymes plasmepsin I and II devoid of cathepsin D inhibitory activity.
    Ersmark K; Feierberg I; Bjelic S; Hamelink E; Hackett F; Blackman MJ; Hultén J; Samuelsson B; Aqvist J; Hallberg A
    J Med Chem; 2004 Jan; 47(1):110-22. PubMed ID: 14695825
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fighting malaria: structure-guided discovery of nonpeptidomimetic plasmepsin inhibitors.
    Huizing AP; Mondal M; Hirsch AK
    J Med Chem; 2015 Jul; 58(13):5151-63. PubMed ID: 25719272
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Flap Dynamics in Aspartic Proteases: A Computational Perspective.
    Mahanti M; Bhakat S; Nilsson UJ; Söderhjelm P
    Chem Biol Drug Des; 2016 Aug; 88(2):159-77. PubMed ID: 26872937
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A dual target of Plasmepsin IX and X: Unveiling the atomistic superiority of a core chemical scaffold in malaria therapy.
    Munsamy G; Agoni C; Soliman MES
    J Cell Biochem; 2019 May; 120(5):7876-7887. PubMed ID: 30430636
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.